Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study

References

• Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961–965.
   PubMed Web of Science ®Google Scholar
• Chi BH, Bolton-Moore C, Holmes CB. Prevention of mother-to-child HIV transmission within the continuum of maternal, newborn, and child health services. Curr Opin HIV AIDS. 2013;8(5):498–503.
   PubMed Web of Science ®Google Scholar
• Frentz D, Van de Vijver DA, Abecasis AB, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014;14:407.
   PubMed Web of Science ®Google Scholar
• Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015;12(4):e1001810.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Stover J, Cambiano V, et al. Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa. J Infect Dis. 2017;215(9):1362–1365.
   PubMed Web of Science ®Google Scholar
• Aghokeng AF, Monleau M, Eymard-Duvernay S, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis. 2014;58(1):99–109.
   PubMed Web of Science ®Google Scholar
• World Health Organization. HIV/AIDS.WHO HIV drug resistance report 2012. Available from: http://www.who.int/hiv/pub/drugresistance/report2012/en/ Accessed March 1, 2015.
   Google Scholar
• Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–371.
   PubMed Web of Science ®Google Scholar
• Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–1669.
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Win MM, Kiertiburanakul S, Phonrat B, Maek-a-nantawat W. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting. Int J STD AIDS. 2012;23(5):316–318.
   PubMed Web of Science ®Google Scholar
• Pham QD, Huynh TK, Luong TT, Tran T, Vu TX, Truong LX. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam. HIV Clin Trials. 2013;14(1):34–44.
   PubMed Web of Science ®Google Scholar
• Sanguansittianant S, Nooroon N, Phaengchomduan P, Ammaranond P. Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010. J Clin Lab Anal. 2013;27(5):346–353.
   PubMed Web of Science ®Google Scholar
• Lai CC, Hung CC, Chen MY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother. 2012;67(5):1254–1260.
   PubMed Web of Science ®Google Scholar
• Lai CC, Liu WC, Fang CT, et al. Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. J Antimicrob Chemother. 2016;71(1):226–234.
   PubMed Web of Science ®Google Scholar
• Stanford University HIV Drug Resistance Database, HIVdb version 8.2. Available from: https://hivdb.stanford.edu/. Accessed April 10, 2016.
   Google Scholar
• Wensing AM, Calvez V, Günthard HF, et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med. 2017;24(4):132–133.
   PubMedGoogle Scholar
• Chang SY, Lin PH, Cheng CL, et al. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan. Sci Rep. 2016;6:35779.
   PubMed Web of Science ®Google Scholar
• Yang WL, Kouyos RD, Scherrer AU, et al. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. J Antimicrob Chemother. 2015;70(12):3323–3331.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–1307.
   PubMed Web of Science ®Google Scholar
• Blanco JL, Montaner JS, Marconi VC, et al. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir+emtricitabine/lamivudine+efavirenz administered on a multiple tablet therapy. AIDS. 2014;28(17):2531–2539.
   PubMed Web of Science ®Google Scholar
• Hazen RJ, Harvey RJ, St Clair MH, et al. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Agents Chemother. 2005;49(11):4465–4473.
   PubMed Web of Science ®Google Scholar
• Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(6):1851–1856.
   PubMed Web of Science ®Google Scholar
• Rokx C, Fibriani A, van de Vijver DA, et al. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort. Clin Infect Dis. 2015;60(1):143–153.
   PubMed Web of Science ®Google Scholar
• TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16(5):565–575.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; 2013. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed September 20, 2016.
   Google Scholar
• Boyd MA, Moore CL, Molina JM, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015;2(2):e42–e51.
   PubMed Web of Science ®Google Scholar
• Rusine J, Asiimwe-Kateera B, van de Wijgert J, et al. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One. 2013;8(8):e64345.
   PubMed Web of Science ®Google Scholar
• Aghokeng AF, Kouanfack C, Eymard-Duvernay S, et al. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months’ antiretroviral therapy experience in Cameroon. J Int AIDS Soc. 2013;16:18004.
   PubMed Web of Science ®Google Scholar
• Jiamsakul A, Sungkanuparph S, Law M, et al. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia. J Int AIDS Soc. 2014;17:19053.
   PubMed Web of Science ®Google Scholar